SYSTEM DELIVERY AND REGULATED EXPRESSION OF PARACRIN GENES FOR TREATMENT OF CARDIOVASCULAR AND OTHER DISEASES

摘要

1. A method of treating, improving, or protecting (protecting) an individual or patient from a disease, infection, or condition sensitive to an elevated or stable level of a paracrine peptide or polypeptide in vivo, comprising: (a) (i) (i) providing a nucleic acid or a gene encoding a paracrine polypeptide operably linked to a transcriptional regulatory sequence; or an expression agent, vector, recombinant virus or equivalent, comprising a nucleic acid encoding a paracrine factor or gene, or a nucleic acid expressing a paracrine polypeptide, transcript or mRNA, the expression agent, vector, recombinant virus, or equivalent, may express an encoding paracrine factor nucleic acid, gene, transcript or mRNA in a cell or in vivo; and (ii) introducing or delivering a paracrine polypeptide of a nucleic acid, gene, transcript or mRNA operably linked to a transcription regulatory sequence, or an expression agent, vector, recombinant virus or equivalent, in a cell or individual or patient in need thereof, and by treatment, improvement or protection (protection) of an individual or patient from a disease, infection or condition sensitive to an elevated or stable level of a paracrine polypeptide; (b) cn person (a) according to which the expression agent, vector, recombinant virus or equivalent is or contains: adeno-associated virus (AAV), lentiviral vector or adenovirus vector, AAV serotype AAV5, AAV6, AAV8 or AAV9, originating from rhesus monkey AAV or poppy-derived